---
title: "Claseprubart (DNTH103) in Chronic inflammatory demyelinating polyneuropathy: DNTH103-AU-001"
description: "Formulary evidence on Claseprubart (DNTH103) in Chronic inflammatory demyelinating polyneuropathy: DNTH103-AU-001. Covers Objective, Location and study date, Study design, Eligibility criteria, Treatment, Study outcomes, and 3 further headings. 46 evidence topics quoted from 9 sources."
canonical: "https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/clinical-evidence/dnth103-au-001"
published: "2026-11-15T22:20:57-05:00"
modified: "2026-11-17T19:46:25-05:00"
---

# Claseprubart (DNTH103) in Chronic inflammatory demyelinating polyneuropathy: DNTH103-AU-001

<a id="heading-3.1.2"></a>

## 3.1.2 DNTH103-AU-001

<a id="heading-3.1.2.1"></a>

### 3.1.2.1 Objective

<a id="topic-3.1.2.1-1"></a>

#### Primary objectives in the Part A and Part B registry record

> “To evaluate the safety and tolerability of DNTH103 when administered IV or SC as a single dose in healthy adult volunteers.”
> “To evaluate the safety and tolerability of DNTH103 when administered IV or SC as multiple doses in healthy adult volunteers.”

Source: [ANZCTR ACTRN12622001265763](https://anzctr.org.au/ACTRN12622001265763.aspx)

<a id="topic-3.1.2.1-2"></a>

#### Secondary objectives in the Part A and Part B registry record

> “To evaluate the pharmacokinetics (PK) of DNTH103 when administered IV or SC as a single dose in healthy adult volunteers.”
> “To evaluate the immunogenicity of DNTH103 when administered IV or SC as a single dose in healthy adult volunteers.”
> “To evaluate the effect of DNTH103 on the classical complement pathway when administered IV or SC as a single dose in healthy adult volunteers.”

Source: [ANZCTR ACTRN12622001265763](https://anzctr.org.au/ACTRN12622001265763.aspx)

<a id="topic-3.1.2.1-3"></a>

#### Part C objectives: pharmacokinetics after human normal immunoglobulin G

> “To evaluate the pharmacokinetics (PK) of DNTH103 when administered IV following administration of IgG, as a single dose in healthy adult volunteers.”
> “To evaluate the PK of DNTH103 when administered SC following administration of IgG, as a single dose in healthy adult volunteers.”
> “To evaluate the immunogenicity of DNTH103 when administered IV following administration of IgG as a single dose in healthy adult volunteers.”
> “To evaluate the effect of DNTH103 on the classical complement pathway when administered IV following administration of IgG as a single dose in healthy adult volunteers.”

Source: [ANZCTR ACTRN12624000352505](https://anzctr.org.au/ACTRN12624000352505.aspx)

<a id="topic-3.1.2.1-4"></a>

#### Objectives stated by the company at study start and at top-line results

> “Data from this Phase 1 study will provide important information about the safety, tolerability, pharmacokinetics and pharmacodynamics of DNTH103 in healthy adult volunteers across single and multiple ascending dose cohorts”

Source: [Dianthus Therapeutics (2022)](https://investor.dianthustx.com/news-releases/news-release-details/dianthus-therapeutics-announces-first-participant-dosed-phase-1)

> “The Phase 1 healthy volunteer study was designed to validate the extended half-life, potent classical pathway inhibition, and potentially differentiated safety profile of DNTH103.”

Source: [Dianthus Therapeutics (2023)](https://investor.dianthustx.com/news-releases/news-release-details/dianthus-therapeutics-announces-positive-top-line-phase-1-data)

<a id="heading-3.1.2.2"></a>

### 3.1.2.2 Location and Study Date

<a id="topic-3.1.2.2-1"></a>

#### Registration, recruitment dates, and status of Parts A and B

> “Date registered 23/09/2022”
> “Type of registration Prospectively registered”
> “Recruitment status Completed”
> “Date of first participant enrolment Anticipated 17/11/2022 Actual 19/11/2022”
> “Date of last participant enrolment Anticipated 31/03/2024 Actual 18/03/2024”
> “Date of last data collection Anticipated 15/09/2024 Actual 6/01/2025”

Source: [ANZCTR ACTRN12622001265763](https://anzctr.org.au/ACTRN12622001265763.aspx)

<a id="topic-3.1.2.2-2"></a>

#### Study location, sponsors, and ethics committee

> “Recruitment outside Australia Country [1] New Zealand State/province [1] Christchurch”
> “Primary sponsor type Commercial sector/Industry Name Dianthus Therapeutics, Inc.”
> “Secondary sponsor category [1] Commercial sector/Industry Name [1] Avance Clinical Pty Ltd”
> “Ethics committee name [1] Southern Health and Disability Ethics Committee”

Source: [ANZCTR ACTRN12622001265763](https://anzctr.org.au/ACTRN12622001265763.aspx)

<a id="topic-3.1.2.2-3"></a>

#### Registration, recruitment dates, and status of Part C

> “Date registered 27/03/2024”
> “Type of registration Retrospectively registered”
> “This record is a sub study of ACTRN12622001265763”
> “Date of first participant enrolment Anticipated Actual 12/12/2023”
> “Date of last participant enrolment Anticipated Actual 18/03/2024”
> “Date of last data collection Anticipated Actual 6/01/2025”

Source: [ANZCTR ACTRN12624000352505](https://anzctr.org.au/ACTRN12624000352505.aspx)

<a id="topic-3.1.2.2-4"></a>

#### First participant dosed, November 2022

> “November 30, 2022 – Dianthus Therapeutics, a biotechnology company dedicated to advancing the next generation of antibody complement therapeutics, today announced that the first healthy volunteers have been dosed in a Phase 1 clinical trial of its lead monoclonal antibody, DNTH103.”

Source: [Dianthus Therapeutics (2022)](https://investor.dianthustx.com/news-releases/news-release-details/dianthus-therapeutics-announces-first-participant-dosed-phase-1)

<a id="topic-3.1.2.2-5"></a>

#### Trial initiation and top-line data dates reported by the company

> “Ph. 1 HV trial initiated in November 2022”
> “Top-line Ph. 1 data demonstrated potent, long-acting classical pathway inhibition in August 2023”

Source: [Dianthus Therapeutics presentation (2024a)](https://www.sec.gov/Archives/edgar/data/1690585/000095017024002707/dnth-ex99_1.htm)

<a id="topic-3.1.2.2-6"></a>

#### Country of the trial

> “We conducted our Phase 1 clinical trial for claseprubart in New Zealand”

Source: [Dianthus Therapeutics Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1690585/000169058526000006/dnth-20251231.htm)

<a id="heading-3.1.2.3"></a>

### 3.1.2.3 Study Design

<a id="topic-3.1.2.3-1"></a>

#### Single ascending dose and multiple ascending dose parts

> “The study will be conducted in two parts: Part A, the single ascending dose (SAD) portion, and Part B, the multiple ascending dose (MAD) portion. Participants in Part A and Part B will be distinct.”
> “Each cohort will enroll 8 participants with 6 participants randomised to receive DNTH103 and 2 participants randomised to receive placebo. The first two subjects dosed in each cohort will be considered sentinel subjects, one each receiving active study drug and placebo.”
> “The time separation between Part A and Part B is not fixed. Part B will not commence until safety at the higher dose in Part A is determined through an SRC review.”

Source: [ANZCTR ACTRN12622001265763](https://anzctr.org.au/ACTRN12622001265763.aspx)

<a id="topic-3.1.2.3-2"></a>

#### Randomization and blinding of Parts A and B

> “Allocation to intervention Randomised controlled trial”
> “The allocation to DNTH103 or placebo will be performed using a block randomisation algorithm and will be documented in the study randomisation schedule.”
> “This study is a double-blind study. Those blinded to study drug assignment include the Investigator, site staff (other than pharmacists), Sponsor, the PI, clinical study personnel participating in participants’ care or clinical evaluations, and the study participants.”

Source: [ANZCTR ACTRN12622001265763](https://anzctr.org.au/ACTRN12622001265763.aspx)

<a id="topic-3.1.2.3-3"></a>

#### Part C: open-label, uncontrolled single cohort

> “Part C will be open label and will not be placebo controlled.”
> “No sentinel dosing is required.”
> “Part C will be initiated after dosing and SRC review is completed for Part A cohort SAD IV4.”
> “Allocation to intervention Non-randomised trial”
> “Masking / blinding Open (masking not used)”

Source: [ANZCTR ACTRN12624000352505](https://anzctr.org.au/ACTRN12624000352505.aspx)

<a id="topic-3.1.2.3-4"></a>

#### First-in-human design described by the company

> “We evaluated DNTH103 in a first-in-human Phase 1 single ascending dose”
> “clinical trial in New Zealand to explore the safety, tolerability, PK, and pharmacodynamics”

Source: [Dianthus Therapeutics Form 10-K (2025)](https://www.sec.gov/Archives/edgar/data/1690585/000095017025037131/dnth-20241231.htm)

<a id="heading-3.1.2.4"></a>

### 3.1.2.4 Eligibility Criteria

<a id="topic-3.1.2.4-1"></a>

#### Key inclusion criteria

> “Adult males and females, 18 to 65 years of age (inclusive) at Screening.”
> “Body mass index less than or equal to 32 kg/m2, with a body weight (to 1 decimal place) greater than or equal to 45 kg and less than or equal to 100 kg at Screening.”
> “Medically healthy without clinically significant abnormalities (in the opinion of the Investigator) at the Screening visit and after check-in on Day -1, prior to dose administration on Day 1”
> “Previously immunized against encapsulated bacterial pathogens as per country-specific guidelines (Neisseria meningitis, Haemophilus influenza, and Streptococcus pneumonia within past 5 years) or willing and able to be vaccinated during the Screening Period and at least 14 days prior to study drug administration on Day 1.”
> “Healthy volunteers Yes”

Source: [ANZCTR ACTRN12622001265763](https://anzctr.org.au/ACTRN12622001265763.aspx)

<a id="topic-3.1.2.4-2"></a>

#### Key exclusion criteria

> “History or presence of significant cardiovascular, pulmonary, hepatic, renal, haematological, gastrointestinal, endocrine, immunologic, dermatologic or neurological disease, including any acute illness or major surgery within 3 months prior to screening determined by the PI to be clinically significant.”
> “History of autoimmune disease or positive autoantibody test result at Screening.”
> “Estimated creatinine clearance (CrCl) < 60 mL/min during Screening or at check-in day (Day -1) using the Cockcroft-Gault formula or serum creatinine more than 1.5-fold above the ULN.”
> “Administration of any live, attenuated vaccines within 30 days and all other vaccinations within 14 days prior to study drug administration.”
> “Females who are breastfeeding or planning to breast feed at any time during the study.”

Source: [ANZCTR ACTRN12622001265763](https://anzctr.org.au/ACTRN12622001265763.aspx)

<a id="topic-3.1.2.4-3"></a>

#### Part C eligibility

> “Adult males and females, 18 to 65 years of age (inclusive) at Screening.”
> “History of autoimmune disease or positive autoantibody test result at Screening.”
> “Healthy volunteers Yes”

Source: [ANZCTR ACTRN12624000352505](https://anzctr.org.au/ACTRN12624000352505.aspx)

<a id="heading-3.1.2.5"></a>

### 3.1.2.5 Treatment

<a id="topic-3.1.2.5-1"></a>

#### Planned Part A single-dose cohorts

> “Single dose DNTH103 or placebo administered on Day 1 (IV or SC) as follows:”
> “SAD IV1, 1 mg/kg”
> “SAD IV2, 3 mg/kg”
> “SAD IV3, 10 mg/kg”
> “SAD IV4, 30 mg/kg”
> “SAD IV5, 60 mg/kg”
> “SAD SC1, 300 mg”
> “SAD SC2, 600 mg”

Source: [ANZCTR ACTRN12622001265763](https://anzctr.org.au/ACTRN12622001265763.aspx)

<a id="topic-3.1.2.5-2"></a>

#### Planned Part B multiple-dose cohorts

> “DNTH103 or placebo is scheduled to be administered at 2-week intervals on Day 1, Day 15 and Day 29 (total of three doses) as follows:”
> “MAD SC1, 300 mg”
> “MAD SC2, 600 mg”

Source: [ANZCTR ACTRN12622001265763](https://anzctr.org.au/ACTRN12622001265763.aspx)

<a id="topic-3.1.2.5-3"></a>

#### Placebo comparator

> “Placebo (matching IV infusion or SC injection) and a sterile saline for IV injection, or excipient alone for SC injection.”

Source: [ANZCTR ACTRN12622001265763](https://anzctr.org.au/ACTRN12622001265763.aspx)

<a id="topic-3.1.2.5-4"></a>

#### Dose cohorts reported as dosed

> “We reported data from 60 healthy volunteers that have been dosed across eight cohorts, including six SAD cohorts: 1mg/kg intravenous”
> “10mg/kg I.V., 30mg/kg I.V., 50mg/kg I.V., 300mg S.C. and 600mg S.C.; and two MAD cohorts: 300mg S.C. and 600mg. S.C.”

Source: [Dianthus Therapeutics Form 10-K (2025)](https://www.sec.gov/Archives/edgar/data/1690585/000095017025037131/dnth-20241231.htm)

<a id="topic-3.1.2.5-5"></a>

#### Part C: intravenous immunoglobulin before a single dose of DNTH103

> “Single dose DNTH103, administered on Day 1 after administration of Privigen NZ solution for IV infusion on Days -8 and -7”
> “IV7, 0.5 g/kg of body weight per day for 2 consecutive days (total dose: 1 g/kg)”
> “Investigational Product: DNTH103 IV infusion, 1 week after Privigen NZ solution:”
> “IV7, 10 mg/kg”
> “Investigational Product: DNTH103 SC injection, 1 week after Privigen NZ solution:”
> “IV7, 600 mg”

Source: [ANZCTR ACTRN12624000352505](https://anzctr.org.au/ACTRN12624000352505.aspx)

<a id="heading-3.1.2.6"></a>

### 3.1.2.6 Study Outcomes

<a id="heading-3.1.2.6.1"></a>

#### 3.1.2.6.1 Rationale for Using Treatment-emergent Adverse Events as the Primary Endpoint

<a id="topic-3.1.2.6.1-1"></a>

##### Primary safety endpoints and adverse event grading

> “Incidence, severity and relationship of treatment-emergent adverse events (TEAE)”
> “Incidence, severity and relationship of adverse events of special interest”
> “Incidence, severity and relationship of treatment-emergent adverse events (TEAE) and AEs of special interest graded using the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) (Version 5).”
> “Final Safety Follow Up (determined when the participant’s CH50 level has met normalization criteria).”

Source: [ANZCTR ACTRN12622001265763](https://anzctr.org.au/ACTRN12622001265763.aspx)

<a id="topic-3.1.2.6.1-2"></a>

##### Safety as the purpose of a first-in-human study

> “This is a first in human study for DNTH103.”

Source: [ANZCTR ACTRN12622001265763](https://anzctr.org.au/ACTRN12622001265763.aspx)

> “Claseprubart Phase 1 healthy volunteer study was designed to validate extended half-life, potency and safety”
> “Safety, PK, and PD measured by percent classical pathway inhibition quantified in each cohort”

Source: [Dianthus Therapeutics presentation (2026a)](https://www.sec.gov/Archives/edgar/data/1690585/000119312526009898/dnth-ex99_1.htm)

<a id="topic-3.1.2.6.1-3"></a>

##### Infection risk with complement inhibition

> “by leaving the lectin and alternative pathways intact, the risk of infection from encapsulated bacteria is lower for DNTH103 versus commonly used C5 and C3 inhibitors.”

Source: [Dianthus Therapeutics (2022)](https://investor.dianthustx.com/news-releases/news-release-details/dianthus-therapeutics-announces-first-participant-dosed-phase-1)

<a id="topic-3.1.2.6.1-4"></a>

##### Secondary pharmacokinetic, pharmacodynamic, and immunogenicity endpoints

> “Maximum concentration (Cmax)”
> “Terminal elimination half-life (t½)”
> “Absolute bioavailability (Fabs)”
> “Complement system classical pathway (CP) inhibition measures in serum ex vivo by the WIESLAB® assay”
> “CH50 (complement haemolysis 50%) in serum ex vivo”
> “Incidence of anti-drug antibody (ADA) to DNTH103”

Source: [ANZCTR ACTRN12622001265763](https://anzctr.org.au/ACTRN12622001265763.aspx)

<a id="topic-3.1.2.6.1-5"></a>

##### Part C: pharmacokinetics as the primary endpoint

> “Type of endpoint/s Pharmacokinetics”

Source: [ANZCTR ACTRN12624000352505](https://anzctr.org.au/ACTRN12624000352505.aspx)

<a id="heading-3.1.2.7"></a>

### 3.1.2.7 Statistical Analysis Description

<a id="heading-3.1.2.7.1"></a>

#### 3.1.2.7.1 Number of Participants (Planned and Analyzed)

<a id="topic-3.1.2.7.1-1"></a>

##### Planned enrollment and sample size basis in the Part A and Part B registry record

> “Part A: Up to approximately 72 participants are planned to be enrolled as follows:”
> “56 healthy volunteers will be enrolled into seven SAD cohorts, five cohorts receiving study drug as an intravenous (IV) infusion and two receiving study drug as a subcutaneous (SC) injection.”
> “Part B: Up to approximately 24 participants are planned to be enrolled as follows:”
> “As such, no formal sample size calculations have been performed. The number of participants in each treatment arm is considered sufficient to achieve the objectives of the study.”

Source: [ANZCTR ACTRN12622001265763](https://anzctr.org.au/ACTRN12622001265763.aspx)

<a id="topic-3.1.2.7.1-2"></a>

##### Final accrual in the registry records, last updated June 2025

> “Date last updated 8/06/2025”
> “Sample size Target 96 Accrual to date Final 68”

Source: [ANZCTR ACTRN12622001265763](https://anzctr.org.au/ACTRN12622001265763.aspx)

> “Up to a maximum of 8 participants will be enrolled in a single cohort (IV7)”
> “Sample size Target 8 Accrual to date Final 9”

Source: [ANZCTR ACTRN12624000352505](https://anzctr.org.au/ACTRN12624000352505.aspx)

<a id="topic-3.1.2.7.1-3"></a>

##### Participants in the top-line analysis, September 2023

> “Top-line data across seven single and multiple ascending dose cohorts with 52 healthy volunteers confirmed its approximately 60-day half-life and highly potent classical pathway inhibition”

Source: [Dianthus Therapeutics (2023)](https://investor.dianthustx.com/news-releases/news-release-details/dianthus-therapeutics-announces-positive-top-line-phase-1-data)

<a id="topic-3.1.2.7.1-4"></a>

##### Participants by part reported in January 2024

> “44 HVs enrolled into six cohorts: Placebo (N= up to 2) Treated (N= up to 6)”
> “16 HVs enrolled into two cohorts: Placebo (N= up to 2) Treated (N= up to 6)”
> “Data comprised of 60 HVs from 8 cohorts”

Source: [Dianthus Therapeutics presentation (2024a)](https://www.sec.gov/Archives/edgar/data/1690585/000095017024002707/dnth-ex99_1.htm)

<a id="topic-3.1.2.7.1-5"></a>

##### Participants reported in the annual report filed March 2025

> “Data from DNTH103’s Phase 1 clinical trial in 60 healthy volunteers across eight dose cohorts validates the extended half-life and potent classical pathway inhibition and supports a potentially differentiated safety profile of DNTH103.”

Source: [Dianthus Therapeutics Form 10-K (2025)](https://www.sec.gov/Archives/edgar/data/1690585/000095017025037131/dnth-20241231.htm)

<a id="heading-3.1.2.7.2"></a>

#### 3.1.2.7.2 Description of Analysis Sets

<a id="topic-3.1.2.7.2-1"></a>

##### Safety, pharmacokinetic, pharmacodynamic, and immunogenicity populations

> “The safety population will consist of all randomised participants who received any amount of study drug. Participants will be analysed according to actual treatment received.”
> “The PK population will include all randomised participants who received treatment where there is at least one post-dose measurement of serum PK concentration data.”
> “The PD population will include all randomised participants who receive any amount of study treatment, who have at least 1 evaluable post-dose PD parameter and will be analysed based on the actual treatment received.”
> “The immunogenicity population will include all randomised participants who receive any amount of study treatment, who have at least 1 evaluable post-dose immunogenicity parameter, and will be analysed based on the actual treatment received.”

Source: [ANZCTR ACTRN12622001265763](https://anzctr.org.au/ACTRN12622001265763.aspx)

<a id="heading-3.1.2.8"></a>

### 3.1.2.8 Results

<a id="heading-3.1.2.8.1"></a>

#### 3.1.2.8.1 Participant Disposition

<a id="topic-3.1.2.8.1-1"></a>

##### Participants who completed dosing, as of December 2023

> “In completed cohorts, 60 healthy volunteers completed dosing as of December 2023”

Source: [Dianthus Therapeutics presentation (2024a)](https://www.sec.gov/Archives/edgar/data/1690585/000095017024002707/dnth-ex99_1.htm)

> “60 healthy volunteers completed dosing as of December 2023 across these eight cohorts”

Source: [Dianthus Therapeutics presentation (2026a)](https://www.sec.gov/Archives/edgar/data/1690585/000119312526009898/dnth-ex99_1.htm)

<a id="topic-3.1.2.8.1-2"></a>

##### Completion of treatment after injection site reactions

> “No intervention was required and both participants completed treatment”

Source: [Dianthus Therapeutics presentation (2024a)](https://www.sec.gov/Archives/edgar/data/1690585/000095017024002707/dnth-ex99_1.htm)

<a id="heading-3.1.2.8.2"></a>

#### 3.1.2.8.2 Baseline Characteristics

No evidence found.

<a id="heading-3.1.2.8.3"></a>

#### 3.1.2.8.3 Efficacy Results

<a id="topic-3.1.2.8.3-1"></a>

##### Pharmacokinetic results: half-life and dose proportionality

> “DNTH103 demonstrated a ~60-day half-life and IC90 of 87 µg/mL”
> “I.V. SAD: Linear PK with Exposure Proportional Across Doses”
> “S.C. MAD: Strong Accumulation with Q2W Dosing”

Source: [Dianthus Therapeutics presentation (2024a)](https://www.sec.gov/Archives/edgar/data/1690585/000095017024002707/dnth-ex99_1.htm)

> “Additionally, based on data from this clinical trial, DNTH103 has a half-life of approximately 60 days.”

Source: [Dianthus Therapeutics Form 10-K (2025)](https://www.sec.gov/Archives/edgar/data/1690585/000095017025037131/dnth-20241231.htm)

<a id="topic-3.1.2.8.3-2"></a>

##### Pharmacodynamic results: classical pathway inhibition and simulated steady state

> “With these data, we conducted a PK simulation that demonstrates the steady state serum concentration of DNTH103, when dosed 300mg S.C. Q2W following an initial I.V. loading dose, exceeds the serum concentration required to surpass 90% classical pathway inhibition in a hemolytic assay”
> “estimated to be 87ug/mL”
> “We believe, based on published scientific literature related to other complement therapies, that the IC90 will be sufficient to achieve clinical activity in patients with gMG, CIDP, and MMN.”

Source: [Dianthus Therapeutics Form 10-K (2025)](https://www.sec.gov/Archives/edgar/data/1690585/000095017025037131/dnth-20241231.htm)

> “Simulation using data from 60 healthy volunteers dosed across multiple cohorts demonstrates potent inhibition with infrequent S.C. dosing”
> “600mg S.C. Q2W dosing surpasses IC95, currently calculated at 149 µg/mL”

Source: [Dianthus Therapeutics presentation (2024a)](https://www.sec.gov/Archives/edgar/data/1690585/000095017024002707/dnth-ex99_1.htm)

<a id="topic-3.1.2.8.3-3"></a>

##### Dose selection for later trials based on phase 1 data

> “Ph. 1 data in 2023 showed potency and long half-life, and DNTH103 was generally well tolerated, allowing for 300mg/2mL Q2W S.C. dosing”

Source: [Dianthus Therapeutics presentation (2024b)](https://www.sec.gov/Archives/edgar/data/1690585/000095017024135775/dnth-ex99_1.htm)

> “Phase 1 data estimated IC90 at ~87 µg/mL, leading to target dose of 300mg/2mL in Ph. 2 to achieve steady state >IC90”
> “Highest dose used in Phase 2 trial was single I.V. loading dose of 20mg/kg”

Source: [Dianthus Therapeutics presentation (2026a)](https://www.sec.gov/Archives/edgar/data/1690585/000119312526009898/dnth-ex99_1.htm)

<a id="topic-3.1.2.8.3-4"></a>

##### Part C pharmacokinetics after immunoglobulin G

No evidence found.

<a id="heading-3.1.2.8.4"></a>

#### 3.1.2.8.4 Health-related Quality of Life and Patient-reported Outcomes

Not applicable.

<a id="heading-3.1.2.8.5"></a>

#### 3.1.2.8.5 Safety Results

<a id="topic-3.1.2.8.5-1"></a>

##### Overall tolerability, serious adverse events, and infections

> “The results also demonstrated DNTH103 was generally well tolerated with no serious adverse events or complement-related infections.”

Source: [Dianthus Therapeutics (2023)](https://investor.dianthustx.com/news-releases/news-release-details/dianthus-therapeutics-announces-positive-top-line-phase-1-data)

> “Claseprubart was generally well tolerated with no SAEs or complement-related infections.”

Source: [Dianthus Therapeutics Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1690585/000169058526000006/dnth-20251231.htm)

<a id="topic-3.1.2.8.5-2"></a>

##### Adverse events reported across the eight cohorts

> “DNTH103 was generally well tolerated, with a favorable safety profile in Phase 1”
> “No standard safety lab findings (hematology, chemistry, coagulation LFTS and renal function)”
> “No serious adverse events”
> “No infection adverse event signal and no infections related to encapsulated bacteria”
> “Five participants experienced mild/moderate Treatment Related AEs”

Source: [Dianthus Therapeutics presentation (2024a)](https://www.sec.gov/Archives/edgar/data/1690585/000095017024002707/dnth-ex99_1.htm)

<a id="topic-3.1.2.8.5-3"></a>

##### Injection site reactions, infusion events, and vomiting

> “Two participants (one in each 300mg and 600mg S.C. MAD cohorts) had a mild or moderate injection site reactions (ISRs)”
> “One participant experienced several non-specific AEs during infusion; infusion was paused for 8 minutes and restarted at the same rate without sequelae”
> “One participant in 600mg S.C. SAD reported vomiting on Day 1, which resolved on same day”

Source: [Dianthus Therapeutics presentation (2024a)](https://www.sec.gov/Archives/edgar/data/1690585/000095017024002707/dnth-ex99_1.htm)

<a id="topic-3.1.2.8.5-4"></a>

##### Antinuclear antibody positivity in the 50 mg/kg intravenous cohort

> “Two participants in 50mg/kg SAD I.V.1 cohort became ANA”
> “positive at Day 57; both participants had no evidence of SLE and both tested negative for dsDNA”
> “One participant subsequently tested negative for ANA in a one-month safety follow-up post Day 57”
> “Other participant experienced inflammatory arthritis and tested negative on broader autoimmune panel”
> “Non-specific indicator of autoimmune disease present in up to 25% of healthy individuals”

Source: [Dianthus Therapeutics presentation (2024a)](https://www.sec.gov/Archives/edgar/data/1690585/000095017024002707/dnth-ex99_1.htm)

<a id="topic-3.1.2.8.5-5"></a>

##### Part C safety

No evidence found.

<a id="heading-3.1.2.9"></a>

### 3.1.2.9 Study Limitations

<a id="topic-3.1.2.9-1"></a>

#### Summary

DNTH103-AU-001 enrolled healthy adults aged 18 to 65 years and excluded people with a history of autoimmune disease, so its safety, pharmacokinetic, and pharmacodynamic findings come from a population without the diseases claseprubart is being developed to treat, and the company states that the same results may not be seen in patients in later trials. Each dose cohort was planned with 8 participants (6 receiving DNTH103 and 2 receiving placebo); the company's top-line announcement reported 52 healthy volunteers in 7 single and multiple ascending dose cohorts, and later company documents reported 60 healthy volunteers in 8 cohorts who completed dosing as of December 2023, while the registry records a final accrual of 68 for Parts A and B and 9 for the open-label, uncontrolled Part C. The Parts A and B registry record lists recruitment in Christchurch, New Zealand, the company states that the phase 1 trial was conducted in New Zealand, and both registry records state that no documents have been uploaded by study researchers, so the available results come from company press releases, presentations, and annual reports, and no Part C result has been reported. The company states that FDA acceptance of data from trials conducted outside the United States is subject to conditions the FDA imposes.

Source: [ANZCTR ACTRN12622001265763](https://anzctr.org.au/ACTRN12622001265763.aspx); [ANZCTR ACTRN12624000352505](https://anzctr.org.au/ACTRN12624000352505.aspx); [Dianthus Therapeutics (2023)](https://investor.dianthustx.com/news-releases/news-release-details/dianthus-therapeutics-announces-positive-top-line-phase-1-data); [Dianthus Therapeutics presentation (2024a)](https://www.sec.gov/Archives/edgar/data/1690585/000095017024002707/dnth-ex99_1.htm); [Dianthus Therapeutics Form 10-K (2025)](https://www.sec.gov/Archives/edgar/data/1690585/000095017025037131/dnth-20241231.htm); [Dianthus Therapeutics Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1690585/000169058526000006/dnth-20251231.htm)

<a id="topic-3.1.2.9-2"></a>

#### Results limited to healthy volunteers and phase 1 data

> “We currently have only preclinical data and data from our Phase 1 clinical trial regarding properties of DNTH103 and the same results may not be seen in patients in our later stage trials.”

Source: [Dianthus Therapeutics Form 10-K (2025)](https://www.sec.gov/Archives/edgar/data/1690585/000095017025037131/dnth-20241231.htm)

<a id="topic-3.1.2.9-3"></a>

#### No results documents in the registry records

> “Documents added manually No documents have been uploaded by study researchers.”
> “Will the study consider sharing individual participant data? No”

Source: [ANZCTR ACTRN12622001265763](https://anzctr.org.au/ACTRN12622001265763.aspx)

> “Documents added manually No documents have been uploaded by study researchers.”

Source: [ANZCTR ACTRN12624000352505](https://anzctr.org.au/ACTRN12624000352505.aspx)

<a id="topic-3.1.2.9-4"></a>

#### Trial conducted outside the United States

> “Although the FDA may accept data from clinical trials conducted outside the United States, acceptance of this data is subject to conditions imposed by the FDA.”
> “The trial population must also adequately represent the U.S. population, and the data must be applicable to the U.S. population and U.S. medical practice in ways that the FDA deems clinically meaningful.”

Source: [Dianthus Therapeutics Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1690585/000169058526000006/dnth-20251231.htm)

## Related pages
- [Claseprubart (DNTH103): Chronic inflammatory demyelinating polyneuropathy](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy) · [Markdown](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy.md)
- [Claseprubart (DNTH103) in Chronic inflammatory demyelinating polyneuropathy: Terms and abbreviations](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/terms-and-abbreviations.md)
- [Claseprubart (DNTH103): Chronic inflammatory demyelinating polyneuropathy](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/executive-summary) · [Markdown](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/executive-summary.md)
- [Claseprubart (DNTH103) in Chronic inflammatory demyelinating polyneuropathy: Product information and disease description](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/product-information-and-disease-description.md)
- [Claseprubart (DNTH103) in Chronic inflammatory demyelinating polyneuropathy: Clinical evidence](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/clinical-evidence.md)
- [Claseprubart (DNTH103) in Chronic inflammatory demyelinating polyneuropathy: Economic information and modeling report](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/economics) · [Markdown](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/economics.md)
- [Claseprubart (DNTH103) in Chronic inflammatory demyelinating polyneuropathy: References](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/references) · [Markdown](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/references.md)
